Iqvia Holdings Q3 2026 earnings

IQV · 2026-10-27 07:08 BMO ET · 8-K on SEC

Revenue, Adjusted EBITDA and Adjusted Diluted EPS grew double digits year-over-year, with R&D Solutions bookings reaching their strongest level since 2022.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$4,428 million+8.0%—Ex. 99.1, income statement
EPS (GAAP)$2.10+8.8%—Ex. 99.1, income statement
EPS (adjusted)$3.34+11.3%—Ex. 99.1, income statement
Adj. EBITDA$1,032 million+8.7%—Ex. 99.1, income statement
Adj. EBITDA margin23.3%+1.2 pp—Ex. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
Commercial Solutions$1,789 million+6.9%40.4%Up 7.9% at constant currency
R&D Solutions$2,639 million+8.7%59.6%Up 9.1% at constant currency

Margins and costs

  • Gross margin 33.3% (prior 33.4%, change -0.1 pp)
  • Operating expenses $890 million (+6.9% YoY)
  • One-offs in the quarter Restructuring costs $36 million; Acquisition related expenses $8 million; Loss on extinguishment of debt $3 million (YTD)
  • Effective tax rate 21.7% (prior 21.6%, YTD 19.1%)
  • Non-GAAP bridge Adds back purchase accounting amortization ($163m), stock-based compensation ($83m), restructuring ($41m), acquisition expenses ($8m), and other items to GAAP net income.

KPIs

MetricActualPrior quarterPrior yearChange
R&D Solutions Net New Bookings$3.2 billion——+15% YoY
Book-to-bill ratio1.2x———
Operating Cash Flow$825 million———
Free Cash Flow$667 million———
AI agents deployedOver 400———

Guidance

MetricGuidePrior guideChange
Revenue$17,350–$17,500 million—Raised
Adjusted EBITDA$4,025–$4,055 million—Raised
Adjusted Diluted EPS$12.90–$13.00—Raised

What drove it

  • Revenue story Commercial Solutions revenue grew 6.9% YoY; R&D Solutions revenue grew 8.7% YoY. Total revenue grew 8.0% YoY.
  • EPS story Adjusted EPS grew 11.3% YoY, driven by revenue growth and margin expansion.
  • One-off check Restructuring costs $36 million; Acquisition related expenses $8 million; Loss on extinguishment of debt $3 million (YTD).

The good

  • R&D Solutions Net New Bookings up 15% YoY, strongest since 2022
  • Adjusted EBITDA margin expanded 1.2 pp YoY to 23.3%
  • Free Cash Flow $667 million, representing 120% of Adjusted Net Income
  • AI-powered solutions deployment exceeded 400 agents

The bad

  • Commercial Solutions revenue growth (6.9%) lagged R&D Solutions (8.7%)
  • Operating Cash Flow $825 million decreased from $908 million in Q3 2025

The ugly

  • none

Open questions

  • The impact of the $2.1 billion backlog adjustment on future revenue conversion
  • The specific contribution of acquisitions to the raised revenue guidance (250 bps)
  • The sustainability of the 1.2x book-to-bill ratio
Full release

Earnings: IQV — filed 2026-10-27

Iqvia Holdings Inc. (IQV) · Form 8-K, Item 2.02 · Filed · SEC filing

IQVIA Reports Third-Quarter 2026 Results

• Revenue $4,428 million, up 8.0% year-over-year, up 8.6% at constant currency

• GAAP Net Income $350 million, Adjusted EBITDA $1,032 million, up 8.7% year-over-year

• GAAP Diluted Earnings per Share $2.10, Adjusted Diluted Earnings per Share $3.34, up 11.3% year-over-year

• Commercial Solutions Revenue $1,789 million, up 6.9% year-over-year, up 7.9% at constant currency

• R&D Solutions Revenue $2,639 million, up 8.7% year-over-year, up 9.1% at constant currency

• R&D Solutions Net New Bookings $3.2 billion, up 15% year-over-year

• Operating Cash Flow $825 million, and Free Cash Flow $667 million, representing 120% of Adjusted Net Income

• Raising full-year 2026 guidance for Revenue, Adjusted EBITDA and Adjusted Diluted Earnings per Share

• Investor Day to be held on December 1, 2026

RESEARCH TRIANGLE PARK, N.C. – (BUSINESS WIRE) – October 27, 2026 – IQVIA Holdings Inc. (“IQVIA”) (NYSE:IQV), a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries, today reported financial results for the quarter ended September 30, 2026.

Year-Over-Year Comparisons

As previously disclosed, effective January 1, 2026, the company implemented a new, simplified organizational model to strengthen collaboration, enhance efficiency, and support continued growth. As a result, the company reports its results within two segments: Commercial Solutions and Research & Development Solutions (R&DS). In conjunction with this change, prior period segment amounts have been recast to conform to this reporting structure.

Third-Quarter 2026 Operating Results

"IQVIA delivered another record quarter, with revenue, Adjusted EBITDA and Adjusted Diluted EPS all exceeding the high end of our expectations," said Ari Bousbib, chairman and CEO of IQVIA. "Multiple demand indicators continue to validate the strengthening market environment. EBP funding, RFP flow, clinical trial starts, FDA approvals, outsourcing trends, and pipeline growth across clinical and commercial are all favorable. At the same time, the team's ongoing excellent execution delivered margin expansion, strong free cash flow, higher win rates that resulted in our strongest clinical quarterly bookings since 2022, increased penetration of AI-powered solutions with over 400 AI agents deployed to date, and organic growth acceleration year-over-year to double the rate for commercial and nearly triple the rate for clinical."

Revenue for the third quarter of $4,428 million increased 8.0% on a reported basis and 8.6% at constant currency, compared to the third quarter of 2025. Commercial Solutions revenue of $1,789 million increased 6.9% on a reported basis and 7.9% at constant currency. Research & Development Solutions revenue of $2,639 million grew 8.7% on a reported basis and 9.1% at constant currency. Excluding reimbursed expenses, R&DS revenue grew 6.8% on a reported basis.

Third quarter net new bookings were $3.2 billion, up 15% year-over-year, representing a book-to-bill ratio of 1.2x. Last-twelve-month net new bookings were $11.7 billion, up 14% year-over-year.

As previously discussed, the company conducted a detailed review of inactive trials in our backlog estimates. This review resulted in an adjustment to backlog of approximately $2.1 billion. The adjustment has no impact on historical financial results, 2026 guidance, book-to-bill, or next-twelve-month revenue from backlog estimates. As of September 30, 2026, R&DS contracted backlog was $32.6 billion. The company expects approximately $9.4 billion of this backlog to convert to revenue in the next twelve months, representing growth of 10% year-over-year.¹

Third-quarter GAAP Net Income was $350 million and GAAP Diluted Earnings per Share was $2.10. Adjusted EBITDA was $1,032 million, up 8.7% year-over-year. Adjusted Net Income was $557 million and Adjusted Diluted Earnings per Share was $3.34, up 11.3% year-over-year.

Year-to-Date 2026 Operating Results

Revenue for the first nine months of 2026 was $12,947 million, up 8.4% on a reported basis and 7.7% at constant currency, compared to the first nine months of 2025. Commercial Solutions revenue of $5,336 million increased 9.0% on a reported basis and 8.3% at constant currency. Research & Development Solutions revenue of $7,611 million increased 8.0% on a reported basis and 7.4% at constant currency.

GAAP Net Income was $880 million and GAAP Diluted Earnings per Share was $5.24. Adjusted EBITDA was $2,958 million, up 7.9% year-over-year. Adjusted Net Income was $1,576 million and Adjusted Diluted Earnings per Share was $9.38, up 10.4% year-over-year.

Financial Position

As of September 30, 2026, cash and cash equivalents were $2,249 million and debt was $16,067 million, resulting in net debt of $13,818 million. IQVIA’s Net Leverage Ratio was 3.45x trailing twelve-month Adjusted EBITDA. For the third quarter, Operating Cash Flow was $825 million, and Free Cash Flow was $667 million, representing 120% of Adjusted Net Income.

Full-Year 2026 Guidance

The company is raising its full-year 2026 guidance for revenue to be between $17,350 million and $17,500 million, for Adjusted EBITDA to be between $4,025 million and $4,055 million and for Adjusted Diluted Earnings per Share to be between $12.90 and $13.00.

This revenue guidance now anticipates 250 basis points of contribution from acquisitions, including acquisitions the company expects to complete by the end of the year, and approximately 20 basis points of tailwind from foreign exchange.

All financial guidance assumes foreign currency exchange rates as of October 26, 2026 remain in effect for the forecast period.

Investor Day... (truncated):30 p.m. ET. Registration is required to attend the event. More information on the event will be available shortly on the IQVIA Investor Relations website at http://ir.iqvia.com.

Webcast & Conference Call Details

IQVIA will host a conference call at 9:00 a.m. Eastern Time today to discuss its third-quarter 2026 results and full-year 2026 guidance. To listen to the event and view the presentation slides via webcast, join from the IQVIA Investor Relations website at http://ir.iqvia.com. To participate in the conference call, interested parties must register in advance by clicking on this link. Following registration, participants will receive a confirmation email containing details on how to join the conference call, including the dial-in and a unique passcode and registrant ID. At the time of the live event, registered participants connect to the call using the information provided in the confirmation email and will be placed directly into the call.²

About IQVIA

IQVIA (NYSE:IQV) is a leading global provider of clinical research services, commercial insights and healthcare intelligence to the life sciences and healthcare industries. IQVIA’s portfolio of solutions are powered by IQVIA Connected Intelligence™ to deliver actionable insights and services built on high-quality health data, Healthcare-grade AI®, advanced analytics, the latest technologies and extensive domain expertise. IQVIA is committed to using artificial intelligence responsibly, with AI-powered capabilities built on best-in-class approaches to privacy, regulatory compliance and patient safety, and delivering AI to the high standards of trust, scalability and precision demanded by the industry. With approximately 95,000 employees in over 100 countries, including experts in healthcare, life sciences, data science, technology and operational excellence, IQVIA is dedicated to accelerating the development and commercialization of innovative medical treatments to help improve patient outcomes and population health worldwide.

IQVIA is a global leader in protecting individual patient privacy. The company uses a wide variety of privacy-enhancing technologies and safeguards to protect individual privacy while generating and analyzing information on a scale that helps healthcare stakeholders identify disease patterns and correlate with the precise treatment path and therapy needed for better outcomes. IQVIA’s insights and execution capabilities help biotech, medical device and pharmaceutical companies, medical researchers, government agencies, payers and other healthcare stakeholders tap into a deeper understanding of diseases, human behaviors and scientific advances, in an effort to advance their path toward cures. To learn more, visit www.iqvia.com.³

Financial statements

Income Statement

Three Months Ended September 30, — (preliminary and unaudited) (in millions, except per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Revenues4,4284,10012,94711,946
Cost of revenues, exclusive of depreciation and amortization2,9302,7278,6597,952
Selling, general and administrative expenses5695141,6451,531
Depreciation and amortization321286901827
Restructuring costs362015081
Income from operations5725531,5921,555
Interest income-12-13-29-34
Interest expense203189592536
Loss on extinguishment of debt34
Other (income) expense, net-5-3111-5
Income before income taxes and equity in earnings (losses) of unconsolidated affiliates3864081,0151,054
Income tax expense7676195193
Income before equity in earnings (losses) of unconsolidated affiliates310332820861
Equity in earnings (losses) of unconsolidated affiliates4265-14
Net income352332885847
Net income attributable to noncontrolling interests-2-1-5-1
Net income attributable to IQVIA Holdings Inc.350331880846
Earnings per share attributable to common stockholders:Basic2.131.945.294.9
Earnings per share attributable to common stockholders:Diluted2.11.935.244.86
Weighted average common shares outstanding:Basic164.7170.2166.4172.6
Weighted average common shares outstanding:Diluted167171.7168174.1

Income Statement

Three Months Ended September 30, — (preliminary and unaudited) (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net Income Attributable to IQVIA Holdings Inc.350331880846
Provision for income taxes7676195193
Depreciation and amortization321286901827
Interest expense, net191176563502
(Income) loss in unconsolidated affiliates-42-6514
Income from noncontrolling interests2151
Stock-based compensation8355243187
Other expense (income), net (1)2-214323
Loss on extinguishment of debt34
Restructuring and related expenses (2)4130161114
Acquisition related expenses8152931
Adjusted EBITDA1,0329492,9582,742

Income Statement

Three Months Ended September 30, — (preliminary and unaudited) (in millions, except per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net Income Attributable to IQVIA Holdings Inc.350331880846
Provision for income taxes7676195193
Purchase accounting amortization (1)163138436394
(Income) loss in unconsolidated affiliates-42-6514
Income from noncontrolling interests2151
Stock-based compensation8355243187
Other expense (income), net (2)2-214323
Loss on extinguishment of debt34
Restructuring and related expenses (3)4130161114
Acquisition related expenses8152931
Adjusted Pre Tax Income6836251,9301,807
Adjusted tax expense-124-109-349-326
Income from noncontrolling interests-2-1-5-1
Adjusted Net Income5575151,5761,480
Adjusted earnings per share attributable to common stockholders:Basic3.383.039.478.57
Adjusted earnings per share attributable to common stockholders:Diluted3.3439.388.5
Weighted average common shares outstanding:Basic164.7170.2166.4172.6
Weighted average common shares outstanding:Diluted167171.7168174.1

Balance Sheet

September 30, 2026 — (preliminary and unaudited) (in millions, except per share data)

September 30, 2026December 31, 2025
Cash and cash equivalents2,2491,980
Trade accounts receivable and unbilled services, net3,2933,400
Prepaid expenses210162
Income taxes receivable3927
Investments in debt, equity and other securities173161
Other current assets and receivables487519
Total current assets6,4516,249
Property and equipment, net534533
Operating lease right-of-use assets313290
Investments in debt, equity and other securities86108
Investments in unconsolidated affiliates438324
Goodwill16,90016,616
Other identifiable intangibles, net4,7384,962
Deferred income taxes408357
Deposits and other assets, net606505
Total assets30,47429,944
Current liabilities:Accounts payable and accrued expenses3,6763,751
Current liabilities:Unearned income2,3132,118
Current liabilities:Income taxes payable171140
Current liabilities:Current portion of long-term debt1,2441,840
Current liabilities:Other current liabilities373489
Current liabilities:Total current liabilities7,7778,338
Current liabilities:Long-term debt, less current portion14,82313,884
Current liabilities:Deferred income taxes157179
Current liabilities:Operating lease liabilities247225
Current liabilities:Other liabilities679688
Current liabilities:Total liabilities23,68323,314
Stockholders’ equity:Common stock and additional paid-in capital, 400.0 shares authorized as of September 30, 2026 and December 31, 2025, $0.01 par value, 259.8 shares issued and 164.8 shares outstanding as of September 30, 2026; 259.1 shares issued and 169.6 shares outstanding as of December 31, 202511,57611,378
Stockholders’ equity:Retained earnings8,3057,425

Cash Flow

Nine Months Ended September 30, — (preliminary and unaudited) (in millions)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net income885847
Adjustments to reconcile net income to cash provided by operating activities:Depreciation and amortization901827
Adjustments to reconcile net income to cash provided by operating activities:Amortization of debt issuance costs and discount1717
Adjustments to reconcile net income to cash provided by operating activities:Stock-based compensation243187
Adjustments to reconcile net income to cash provided by operating activities:(Earnings) losses from unconsolidated affiliates-6514
Adjustments to reconcile net income to cash provided by operating activities:Loss (gain) on investments, net7-20
Adjustments to reconcile net income to cash provided by operating activities:Benefit from deferred income taxes-97-132
Changes in operating assets and liabilities:Change in accounts receivable, unbilled services and unearned income341442
Changes in operating assets and liabilities:Change in other operating assets and liabilities-231-263
Changes in operating assets and liabilities:Net cash provided by operating activities2,0011,919
Investing activities:Acquisition of property, equipment and software-483-429
Investing activities:Acquisition of businesses, net of cash acquired-589-798
Investing activities:Sales of marketable securities, net32
Investing activities:Investments in unconsolidated affiliates, net of payments received-67-28
Investing activities:Investments in debt and equity securities-20
Investing activities:Proceeds from sale of property, equipment and software75
Investing activities:Other-3
Investing activities:Net cash used in investing activities-1,136-1,201
Financing activities:Proceeds from issuance of debt3,7583,985
Financing activities:Payment of debt issuance costs-49-34
Financing activities:Repayment of debt and principal payments on finance leases-2,458-2,676
Financing activities:Proceeds from revolving credit facility1,3501,375
Financing activities:Repayment of revolving credit facility-2,150-2,200
Financing activities:Payments related to employee stock incentive plans-43-66
Financing activities:Repurchase of common stock-950-1,032
Financing activities:Distributions to noncontrolling interests, net-1
Financing activities:Contingent consideration and deferred purchase price payments-17-26
Financing activities:Other-9-11
Financing activities:Net cash used in financing activities-569-685
Financing activities:Effect of foreign currency exchange rate changes on cash-2779
Financing activities:Increase in cash and cash equivalents269112
Financing activities:Cash and cash equivalents at beginning of period1,9801,702
Financing activities:Cash and cash equivalents at end of period2,2491,814

Cash Flow

Three Months Ended September 30, — (preliminary and unaudited) (in millions)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net Cash provided by Operating Activities8259082,0011,919
Acquisition of property, equipment and software-158-136-483-429
Free Cash Flow6677721,5181,490

Cautionary Statements Regarding Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, including, without limitation, our full-year 2026 guidance. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as “expect,” “assume,” “anticipate,” “intend,” “plan,” “forecast,” “believe,” “seek,” “see,” “will,” “would,” “target,” similar expressions, and variations or negatives of these words that are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Actual results may differ materially from our expectations due to a number of factors, including, but not limited to, the following: business disruptions caused by natural disasters, pandemics, and the public health policy response to any outbreak, and international conflicts or other disruptions outside of our control; most of our contracts may be terminated on short notice, and we may lose or experience delays with large client contracts or be unable to enter into new contracts; the market for our services may not grow as we expect; we may be unable to successfully develop and market new services or enter new markets; imposition of restrictions on our use of data by data suppliers or their refusal to license data to us; any failure by us to comply with contractual, regulatory or ethical requirements under our contracts, including current or future changes to data protection and privacy laws; breaches or misuse of our or our outsourcing partners’ security or communications systems; failure to meet our productivity or business transformation objectives; failure to successfully invest in growth opportunities; our ability to protect our intellectual property rights and our susceptibility to claims by others that we are infringing on their intellectual property rights; the expiration or inability to acquire third party licenses for technology or intellectual property; any failure by us to accurately and timely price and formulate cost estimates for contracts, or to document change orders; hardware and software failures, delays in the operation of our computer and communications systems or the failure to implement system enhancements; the rate at which our backlog converts to revenue; our ability to acquire, develop and implement technology necessary for our business; consolidation in the industries in which our clients operate; risks related to client or therapeutic concentration; government regulators or our customers may limit the number or scope of indications for medicines and treatments or withdraw products from the market, and government regulators may impose new regulatory requirements or may adopt new regulations affecting the biopharmaceutical industry; the risks associated with operating on a global basis, including currency or exchange rate fluctuations and legal compliance, including anti-corruption laws; risks related to the enactment of legislation or the imposition of regulations or other restrictions or actions by governments that create business uncertainty and have the potential to limit trade; changes in accounting standards; general economic conditions in the markets in which we operate, including financial market conditions, inflation, and risks related to sales to government entities; the impact of changes in tax laws and regulations; and our ability to successfully integrate, and achieve expected benefits from, our acquired businesses. In addition, we may not achieve the expected benefits of our reorganized business segment structure.

For a further discussion of the risks relating to our business, see the “Risk Factors” in our annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the Securities and Exchange Commission (the "SEC"), as such factors may be amended or updated from time to time in our subsequent periodic and other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov. These factors should not be construed as exhaustive and should be read in conjunction with the other cautionary statements that are included in this release and in our filings with the SEC. We assume no obligation to update any such forward-looking statement after the date of this release, whether as a result of new information, future developments or otherwise.⁴

Note on Non-GAAP Financial Measures

This release includes information based on financial measures that are not recognized under generally accepted accounting principles in the United States ("GAAP"), such as Adjusted EBITDA, Adjusted Net Income, Adjusted Diluted Earnings per Share, Gross Leverage Ratio, Net Leverage Ratio and Free Cash Flow. Non-GAAP financial measures are presented only as a supplement to the company’s financial statements based on GAAP. Non-GAAP financial information is provided to enhance understanding of the company’s financial performance, but none of these non-GAAP financial measures are recognized terms under GAAP, and non-GAAP measures should not be considered in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP. The company uses non-GAAP measures in its operational and financial decision making, and believes that it is useful to exclude certain items in order to focus on what it regards to be a more meaningful indicator of the underlying operating performance of the business. For example, the company excludes all the amortization of intangible assets associated with acquired customer relationships and backlog, databases, non-compete agreements, trademarks and trade names from non-GAAP expense and income measures as such amounts can be significantly impacted by the timing and size of acquisitions. Although we exclude amortization of acquired intangible assets from our non-GAAP expenses, we believe that it is important for investors to understand that revenue generated from such intangibles is included within revenue in determining net income. As a result, internal management reports feature non-GAAP measures which are also used to prepare strategic plans and annual budgets and review management compensation. The company also believes that investors may find non-GAAP financial measures useful for the same reasons, although investors are cautioned that non-GAAP financial measures are not a substitute for GAAP disclosures.

The non-GAAP financial measures are not presented in accordance with GAAP. Please refer to the schedules attached to this release for reconciliations of non-GAAP financial measures contained herein to the most directly comparable GAAP measures. Our full-year 2026 guidance measures (other than revenue) are provided on a non-GAAP basis without a reconciliation to the most directly comparable GAAP measure because the company is unable to predict with a reasonable degree of certainty certain items contained in the GAAP measures without unreasonable efforts. For the same reasons, the company is unable to address the probable significance of the unavailable information. Such items include, but are not limited to, acquisition related expenses, restructuring and related expenses, stock-based compensation and other items not reflective of the company's ongoing operations.

Non-GAAP measures are frequently used by securities analysts, investors and other interested parties in their evaluation of companies comparable to the company, many of which present non-GAAP measures when reporting their results. Non-GAAP measures have limitations as an analytical tool. They are not presentations made in accordance with GAAP, are not measures of financial condition or liquidity and should not be considered as an alternative to profit or loss for the period determined in accordance with GAAP or operating cash flows determined in accordance with GAAP. Non-GAAP measures are not necessarily comparable to similarly titled measures used by other companies. As a result, you should not consider such performance measures in isolation from, or as a substitute analysis for, the company’s results of operations as determined in accordance with GAAP.

IQVIAFIN

#

#

#⁵

Table 1

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Iqvia Holdings earnings · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.